期刊簡(jiǎn)介預(yù)計(jì)審稿時(shí)間： 偏慢,4-8周

The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.

The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.

With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.

Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).

《免疫藥理學(xué)與免疫毒理學(xué)》雜志致力于針對(duì)免疫系統(tǒng)的臨床前和臨床藥物發(fā)現(xiàn)和開發(fā)。研究涉及各種化合物（包括小分子藥物和生物制劑）對(duì)免疫活性細(xì)胞和免疫反應(yīng)的免疫調(diào)節(jié)作用，以及外來(lái)生物和藥物產(chǎn)生的免疫毒性。只有描述特定化合物（而非提取物）機(jī)制的研究才是該雜志感興趣的。

該雜志將優(yōu)先考慮慢性炎癥、過(guò)敏、自身免疫、癌癥等疾病的免疫治療的臨床前和臨床研究。小分子藥物、疫苗和生物制劑對(duì)中樞免疫靶點(diǎn)的影響以及基于細(xì)胞的治療，包括樹突狀細(xì)胞治療、T 細(xì)胞過(guò)繼轉(zhuǎn)移和干細(xì)胞治療，都是特別感興趣的主題。我們也歡迎針對(duì)免疫系統(tǒng)內(nèi)潛在新藥靶點(diǎn)或免疫藥理學(xué)藥物開發(fā)新技術(shù)的出版物。

該期刊以免疫科學(xué)為重點(diǎn)，關(guān)注藥物開發(fā)、免疫治療和毒理學(xué)，涵蓋感染、過(guò)敏、炎癥、腫瘤免疫學(xué)、退行性疾病、免疫缺陷、神經(jīng)病學(xué)、動(dòng)脈粥樣硬化等領(lǐng)域。

《免疫藥理學(xué)和免疫毒理學(xué)》將接受原創(chuàng)手稿、簡(jiǎn)訊、評(píng)論、小型評(píng)論、評(píng)論、臨床試驗(yàn)和臨床病例，條件是報(bào)告的結(jié)果基于原創(chuàng)、臨床或基礎(chǔ)研究，且未以任何語(yǔ)言在任何期刊上發(fā)表過(guò)（以摘要形式提交給科學(xué)會(huì)議和研討會(huì)的論文除外）。

《Immunopharmacology And Immunotoxicology》(免疫藥理學(xué)和免疫毒理學(xué))編輯部通訊方式為TAYLOR & FRANCIS INC, 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, USA, PA, 19106。如果您需要協(xié)助投稿或潤(rùn)稿服務(wù)，您可以咨詢我們的客服老師。我們專注于期刊咨詢服務(wù)十年，熟悉發(fā)表政策，可為您提供一對(duì)一投稿指導(dǎo)，避免您在投稿時(shí)頻繁碰壁，節(jié)省您的寶貴時(shí)間，有效提升發(fā)表機(jī)率，確保SCI檢索（檢索不了全額退款）。我們視信譽(yù)為生命，多方面確保文章安全保密，在任何情況下都不會(huì)泄露您的個(gè)人信息或稿件內(nèi)容。